Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials

Abstract Objective Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It has a wide range of clinical applications in various cancers and retinal diseases. The drugs entered the Chinese market by a large margin in 2017, and the user population changed to some extent. Th...

Full description

Bibliographic Details
Main Authors: Li Wang, Yibo Fei, Han Qu, Haiyang Zhang, Yuanyuan Wang, Zhenghua Wu, Guorong Fan
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Online Access:https://doi.org/10.1186/s40780-023-00314-w